ANKRD47 Inhibitors
ANKRD47 inhibitors are a class of chemical compounds specifically designed to target the ANKRD47 protein, a member of the ankyrin repeat domain-containing family. ANKRD47 is characterized by the presence of ankyrin repeat motifs, which are structural domains composed of repeating helix-loop-helix structures. These motifs play a crucial role in facilitating protein-protein interactions by creating stable binding surfaces, enabling ANKRD47 to participate in key cellular processes such as signal transduction, protein trafficking, and cellular structural organization. ANKRD47 inhibitors are engineered to disrupt these interactions by binding directly to the ankyrin repeat domains or their interacting partners, effectively preventing ANKRD47 from forming or stabilizing essential protein complexes.
The chemical structure of ANKRD47 inhibitors can vary, including small organic molecules, peptides, and synthetic mimetics. These inhibitors typically target specific hydrophobic pockets or electrostatic interactions within the ankyrin repeats, thereby blocking the natural binding partners of ANKRD47. In some cases, inhibitors are designed to mimic the structural features of ANKRD47's native ligands, competitively binding to the same sites and preventing the formation of functional protein assemblies. Other inhibitors may induce conformational changes in the ankyrin repeat motifs, destabilizing the structural integrity of the protein and impairing its ability to participate in cellular interactions. By inhibiting these molecular interactions, ANKRD47 inhibitors are valuable tools for studying the specific roles of ANKRD47 in various biological pathways, providing insight into the broader regulatory functions of ankyrin repeat domain-containing proteins in cellular systems.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent non-selective inhibitor of protein kinases. By broadly inhibiting protein kinase activity, it can disrupt downstream signaling pathways that may include those involving ANKRD47. If ANKRD47 function depends on phosphorylation events, staurosporine could inhibit its activity by preventing such modifications. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of PI3K (phosphoinositide 3-kinases). PI3K signaling is implicated in a vast array of cellular functions. Inhibition by LY294002 can lead to a reduction in AKT phosphorylation and activity, which in turn could affect cellular processes that ANKRD47 is involved in, leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin specifically inhibits mTOR (mammalian target of rapamycin), which is central to a cellular signaling pathway important for cell growth and proliferation. mTOR inhibition can affect the cytoskeletal organization, potentially affecting ANKRD47 if its function is related to cytoskeletal dynamics. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. The p38 MAPK pathway is involved in inflammatory responses and stress signaling. Inhibition of this pathway could lead to alterations in cellular stress responses, potentially affecting the functional state of ANKRD47 if it is stress-responsive. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, which in turn prevents the activation of ERK, a kinase involved in the MAPK/ERK signaling pathway. If ANKRD47 is regulated by ERK-mediated signaling, inhibition by PD98059 could reduce ANKRD47 activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor, which can lead to the accumulation of misfolded proteins and subsequent cellular stress. If the function of ANKRD47 is sensitive to proteostasis, bortezomib-induced stress could inhibit its activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor, limiting the activation of the ERK pathway. By inhibiting MEK, U0126 could reduce ERK activity and possibly affect the regulation of ANKRD47, assuming it is part of this signaling cascade. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinases), which are critical for controlling apoptosis, cytokine production, and other cellular processes. Inhibition of JNK could lead to altered cell survival signaling, potentially impacting ANKRD47 function if it is involved in these processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, like LY294002, and exerts its effects by covalently binding to the catalytic site of the enzyme. This inhibition could downregulate AKT signaling, indirectly affecting ANKRD47 if it relies on AKT-mediated pathways. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $152.00 $479.00 $632.00 $1223.00 $2132.00 | 33 | |
Trichostatin A is an inhibitor of histone deacetylases (HDACs), which affects chromatin structure and gene expression. If the expression or activity of ANKRD47 is regulated by acetylation status, trichostatin A could lead to its inhibition. | ||||||